Skip to main content

2 Result(s)

within L Bazzola Remove this filter

and

  1. Article

    Open Access

    Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer

    To assess whether the combination of letrozole, metronomic cyclophosphamide and sorafenib (LCS) is well tolerated and shows activity in primary breast cancer (BC).

    L Bazzola, C Foroni, D Andreis, V Zanoni, M R Cappelletti… in British Journal of Cancer (2015)

    Download PDF (1113 KB) View Article

  2. Article

    Open Access

    Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

    The objective of this study was to determine the optimal scheduling of 2.5 mg daily letrozole in neoadjuvant breast cancer patients to obtain pathological complete response (pathCR) and assess Ki-67 expression...

    G Allevi, C Strina, D Andreis, V Zanoni, L Bazzola, S Bonardi… in British Journal of Cancer (2013)

    Download PDF (286 KB) View Article